How to Buy Jazz Pharmaceuticals Stock
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally.
Jazz Pharmaceuticals stock last closed at $108.50, down 1.63% from the previous day, and has decreased 3.73% in one year. It has overperformed other stocks in the Biotechnology industry by 0.73 percentage points. Jazz Pharmaceuticals stock is currently +13.62% from its 52-week low of $95.49, and -26.72% from its 52-week high of $148.06.
There are currently 61.63M JAZZ shares outstanding. The market capitalization of JAZZ is $6.69B. In the last 24 hours, 478,000 JAZZ shares were traded.
How to Buy Jazz Pharmaceuticals Stock
Not sure how to invest in Jazz Pharmaceuticals stock? Here's how.
- Figure out where to buy Jazz Pharmaceuticals stock: You need to choose an online brokerage, but don't worry - we've tried dozens of online brokerages and apps to help you determine where to buy Jazz Pharmaceuticals stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Deposit funds into your brokerage account: Select your payment method and add your information.
- Analyze Jazz Pharmaceuticals stock: The Jazz Pharmaceuticals ticker symbol is JAZZ. Is Jazz Pharmaceuticals stock a good investment? Should you buy shares of JAZZ? How do JAZZ's underlying business fundamentals look? Do top analysts think Jazz Pharmaceuticals is a good buy? Why has JAZZ's stock price moved recently? (Hint: Our stock research tools can help you understand if JAZZ is a good stock to buy).
- Place your JAZZ buy order: Decide if you will purchase JAZZ shares at the current market price or use a limit order to buy JAZZ shares at a specific price.
- Get updates on your JAZZ position: Create a watchlist to important updates regarding your new investment in Jazz Pharmaceuticals stock.
Step 1: Figure out where to buy Jazz Pharmaceuticals stock
You will need an online brokerage account in order to access the NASDAQ market and buy JAZZ stock.
Our recommended brokerage: eToro
Based on our research, eToro is the best place to buy stocks. eToro gives you:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global financial markets: From Technology to Financial Services, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro has a community of more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've selected your brokerage, it's time to fill out some personal info so you can invest in JAZZ stock today.
How to Open a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to open your new brokerage account.
- Submit your details by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've created your account on our top ranked stock app, you can securely and quickly fund your account:
Check out the tutorial below if you need help depositing money into your new brokerage account.
Step 4: Analyze Jazz Pharmaceuticals stock
Once you have decided on the best place to buy Jazz Pharmaceuticals stock, it's important to analyze their stock before you invest, so you can wrap your head around the risk and upside.
Jazz Pharmaceuticals stock data
JAZZ Due Diligence Score
WallStreetZen was designed to help average investors do more accurate fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on JAZZ's stock page.
How is JAZZ stock valued?
Investors use many financial metrics, analyses, models, and charts to gauge JAZZ's true value.
Using relative valuations ratios:
- JAZZ may be undervalued based on its P/E ratio of 13.93x, relative to Biotechnology industry P/E ratio of -108.97x
- JAZZ may be undervalued based on its P/B ratio of 1.6x, relative to Biotechnology industry P/B ratio of 4.66x
- JAZZ could be undervalued based on its PEG ratio of 0.29x
You can do additional valuation analysis on JAZZ's stock here.
A quick look at JAZZ Financials
Passed Financial Due Diligence Checks:
- JAZZ's operating cash flow of $1.56B allows it to safely service it's debt of $5.41B.
- JAZZ profit margin has gone up from 8.6% to 11.9% in the past year.
- There are more short-term assets than short-term liabilities on the JAZZ balance sheet.
Failed Financial Due Diligence Checks:
- JAZZ has a relatively high debt to equity ratio of 1.76.
- There are more long-term liabilities than short-term assets on the JAZZ balance sheet.
- JAZZ earnings of $586.97M is not enough to cover its interest payments.
- Total JAZZ debt is higher than 5 years ago, relative to shareholder equity.
Is JAZZ stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 12 Equities analysts who track JAZZ, the consensus analyst rating on JAZZ is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they investment advice.
Latest JAZZ Analyst Forecasts
Oren Livnat, a top 36% analyst from HC Wainwright & Co. maintains JAZZ with a buy rating and raises their JAZZ price target from $200.00 to $217.00, on Mar 10, 2025.
Ashwani Verma, a bottom 16% analyst from UBS upgrades JAZZ to a strong buy rating and raises their JAZZ price target from $145.00 to $179.00, on Mar 7, 2025.
Gregory Fraser, a top 21% analyst from Truist Securities maintains JAZZ with a strong buy rating and raises their JAZZ price target from $220.00 to $230.00, on Mar 6, 2025.
Truist Securities's Gregory Fraser raised their price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) by 4.5% from $220 to $230 on 2025/03/06. The analyst maintained their Strong Buy rating on the stock.
Following Jazz Pharmaceuticals' announcement that it will buy Chimerix for $935M, or $8.55 per share, Fraser said they adjusted their model.
The deal is likely to close in Q2, before "Dordaviprone PDUFA (Prescription Drug User Fee Act) with priority review set for 2025/08/18," the analyst detailed.
Fraser noted that after the deal closes, Jazz Pharmaceuticals will have ownership of the next-generation, more powerful drug, ONC206, which has demonstrated monotherapy efficacy in a wider range of malignancies in preclinical models.
Balaji Prasad, a bottom 8% analyst from Barclays maintains JAZZ with a strong buy rating and raises their JAZZ price target from $190.00 to $200.00, on Feb 27, 2025.
Charles Duncan, a top 3% analyst from Cantor Fitzgerald downgrades JAZZ to a hold rating and raises their JAZZ price target from $140.00 to $150.00, on Feb 26, 2025.
You can dig deeper into what analysts are saying on the Jazz Pharmaceuticals stock forecast page.
JAZZ Trading Indicators
How are JAZZ Revenues/Earnings doing?
Last year, JAZZ earnings were $482.20M. In the last five year, JAZZ's earnings have gone up by 9.63% per year. This was faster than the Biotechnology industry average of 8.66%.
Last year, JAZZ revenue was $4.06B. In the last 5 year, JAZZ's revenue has grown by 13.18% per year. This was slower than the Biotechnology industry average of 43.24%.
Find out more about JAZZ's earnings and revenue performance here.
Latest Insiders Trades at JAZZ
In the last 12 months, executives and large shareholders at JAZZ have sold more shares than they have bought.
Bruce C. Cozadd, Chairman CEO of JAZZ, was the latest JAZZ insider to sell. They sold $55,000.00 worth of JAZZ stock on Jun 3, 2025.
Learn more about who owns JAZZ shares here.
Does JAZZ stock generate passive income?
No, Jazz Pharmaceuticals doesn't provide an income stream by paying out dividends.
JAZZ Social Trading Data
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Place your JAZZ buy order
You have two main types of orders:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are mostly the best for newer investors. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at an exact price limit, place a limit order.
Press the Open button and your broker will execute the order.
If you require more help with investing in stocks on eToro, click the how to video below:
Step 6: Get updates on your JAZZ position
Now that you own some shares in JAZZ, you'll want to keep up with your investment.
Make a watchlist to track your JAZZ stock.
JAZZ Feed
How to Buy Stock in Jazz Pharmaceuticals
To reiterate, here are the 6 steps to buy Jazz Pharmaceuticals stock:
- Figure out where to buy Jazz Pharmaceuticals stock
- Create your brokerage account
- Deposit funds into your brokerage account
- Analyze Jazz Pharmaceuticals stock
- Place your JAZZ buy order
- Get updates on your JAZZ position
If you are looking for a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to get the latest news on your investment in Jazz Pharmaceuticals, add JAZZ to your watchlist by clicking the button below.
More Stock Buying Guides You Might Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.